Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

CompletedOBSERVATIONAL

Enrollment

272

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

January 17, 2018

Study Completion Date

March 26, 2018

Conditions

Hemophilia A

Interventions

DRUG

Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)

Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds

Trial Locations (10)

Phoenix

Aurora

Washington D.C.

New Orleans

Detroit

Minneapolis

Columbus

Multiple Locations